The global urinary tract infection therapeutics market size is anticipated to expand at a robust CAGR during the forecast period, 2021-2028. The growth of the market is attributed to rising awareness about the urinary tract infection. Moreover, increasing prevalence of diabetes and kidney stones are driving the market growth.
A urinary tract infection (UTI) is an infection in urinary system such as kidney, ureter, bladder, and urethra. UTIs can be caused due to various reasons, including unsafe intercourse, lack of hygiene, and diabetes. UTIs are more common in women than men due to inherent complications in the female reproductive system. According to the World Health Organization (WHO), over one million hospitalizations of women occur each year due to UTIs and it affects almost half the female population around the world.
UTI occurs when there is a compromise of host defense mechanism and a virulent microbe adheres, multiplies, and persists in a portion of the urinary tract. Most commonly, UTI is caused by bacteria, while fungi and viruses can also cause UTI. Urine culture is the gold standards for diagnosis of bacterial UTI.
Identifying the location of infection as well as comorbidities are essential to guide the diagnostic and therapeutic plan. Antimicrobial agents are the mainstay of therapy for bacterial UTI.
Market Trends, Drivers, Restraints, and Opportunities:
- Rising number of combination drugs that are more effective than conventional ones is one of the major drivers that is contributing to the growth of the global urinary tract infection therapeutics market.
- Increasing geriatric population is expected to augment the market growth.
- Lack of awareness about the prevalence of UTI can restrain the growth of the market.
- Rising number of government initiatives to increase the awareness about UTI can create lucrative opportunities for the industry players during the forecast period.
Scope of Urinary Tract Infection Therapeutics Market Report
The report on the global urinary tract infection therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Urinary Tract Infection Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Types (Quinolones, Penicillin & Combinations, Cephalosporin, Tetracycline, Sulphonamides, Nitrofurans, and Others), Indications (Complicated Urinary Tract Infection, and Uncomplicated Urinary Tract Infection)
North America, Latin America, Europe, Asia Pacific and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, and DuPont Nutrition & Biosciences
Urinary Tract Infection Therapeutics Market Segment Insights
Quinolones segment to grow at a rapid pace
Based on types, the market is divided into quinolones, penicillin & combinations, cephalosporin, tetracycline, sulphonamides, nitrofurans, and others. The quinolones segment is anticipated to account for a key share and is anticipated to grow at a robust rate during the forecast period. Quinolones is the most commonly prescribed drug type by physicians Conversely, the cephalosporin segment is expected to grow at a healthy rate in the coming years.
Complicated urinary tract infections segment to account a major market share
Based on indications, the market is divided into complicated urinary tract infection and uncomplicated urinary tract infection. The complicated urinary tract infection segment is anticipated to account for a major share due to rising number of patients getting infected to UTI due to multidrug resistant bacteria, making it more difficult for treatment.
North America to account a considerable market share
On the basis of regions, the market is segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is expected to account for a considerable market share during the forecast period. Growing awareness and prevalence of UTI and increasing incidence of diabetes are driving the regional market growth. The market in Europe is expected to grow at a substantial rate owing to increased accessibility to improved healthcare facilities along with high UTI prevalence among the population.
The global urinary tract infection therapeutics has been segmented on the basis of
- Penicillin & Combinations
- Complicated Urinary Tract Infection
- Uncomplicated Urinary Tract Infection
The major players of the market are Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, DuPont Nutrition & Biosciences.
Companies are focusing on innovation, expansion and acquisitions to expand their market share.